IBM
International Business Machines Corporation
IBM has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over IBM overall, supported by stronger fundamentals.
IBM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Under pressure |
IBM's profitability and cash flow are currently strong, and its revenue is stable, but its balance sheet is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
IBM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $194 | -21% |
| Forward | 19x | $245 | — |
| Current | 21x | $245 | — |
| Fair | 23x | $274 | +12% |
| Expensive | 46x | $538 | +120% |
Historical ranges are pointers, not guarantees.
IBM's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over IBM in the historical PE scenario, which offers more potential upside but is not a forecast.
IBM Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect IBM's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over IBM on the outlook, with more favorable revenue expectations.
IBM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.06 | +11% |
| Q3 2026 | $11.75 | +40% |
| Q2 2026 | $11.29 | +83% |
| Q1 2026 | $11.33 | +94% |
| Q4 2025 | $11.17 | +74% |
| Q3 2025 | $8.38 | +22% |
| Q2 2025 | $6.18 | -32% |
| Q1 2025 | $5.83 | -34% |
| Q4 2024 | $6.43 | -21% |
IBM has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
IBM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.1B | +4.7% |
| Q2 2026 | $17.2B | +1.1% |
| Q1 2026 | $15.9B | +9.5% |
| Q4 2025 | $19.7B | +12% |
| Q3 2025 | $16.3B | +9.1% |
| Q2 2025 | $17B | +7.7% |
| Q1 2025 | $14.5B | +0.5% |
| Q4 2024 | $17.6B | +1% |
IBM's revenue has grown year over year for 13 quarters in a row: $17.1B last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -0.3 points |
| Q2 2026 | 14% | -0.9 points |
| Q1 2026 | 8.7% | +0.8 points |
| Q4 2025 | 21% | +2.2 points |
| Q3 2025 | 15% | +20 points |
| Q2 2025 | 15% | +1.2 points |
| Q1 2025 | 8% | +0.5 points |
| Q4 2024 | 19% | -2.8 points |
IBM has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over IBM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
IBM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +31% |
| Q2 2026 | $2.4B | +59% |
| Q1 2026 | $4.9B | +20% |
| Q4 2025 | $3.7B | -9.2% |
| Q3 2025 | $2.8B | +8.9% |
| Q2 2025 | $1.5B | -19% |
| Q1 2025 | $4.1B | +5% |
| Q4 2024 | $4B | -3.3% |
IBM's free cash flow has been positive every quarter for seven years: $14.7B over the past year, up 18% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over IBM on cash flow, with more consistent year-over-year improvement.
IBM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +260K shares |
| 1 year | +0.5% | +4.6M shares |
| 3 years | +3.2% | +29.9M shares |
| 5 years | +5.3% | +47.6M shares |
| Available history | +2.1% | +19.6M shares |
IBM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IBM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.9x | Elevated |
| Q2 2026 | 3.9x | Elevated |
| Q1 2026 | 4.0x | High |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 5.5x | High |
| Q1 2025 | 5.6x | High |
| Q4 2024 | 4.4x | High |
IBM's net debt is about 3.9 years of its operating earnings (EBITDA), down from 4.2 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over IBM on leverage, with a lower net debt burden relative to earnings.
IBM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.1 | Neutral |
| Stochastic | 74.8 | Neutral |
IBM's weekly RSI is 50 (neutral) and its Stochastic is 75 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
IBM PE vs Technology Sector
| Metric | IBM | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 31 | 35 | 4 pts below |
IBM is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over IBM on valuation relative to its sector.
IBM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $238.6 | 2.6% above |
| 20 week MA | $239.3 | 2.2% above |
| 50 week MA | $256.6 | 4.6% below |
| 100 week MA | $258.5 | 5.3% below |
| 200 week MA | $212.3 | 15% above |
IBM's trend is mixed: it's above three of its five weekly moving averages, and 15% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over IBM on trend strength, trading above more of its moving averages.
IBM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $129.3 | $119.2 | -7.8% |
| 2021 | $119.2 | $130.6 | +9.6% |
| 2022 | $130.6 | $141.7 | +8.4% |
| 2023 | $141.7 | $163.6 | +15% |
| 2024 | $163.6 | $222.8 | +36% |
| 2025 | $222.8 | $305.1 | +37% |
| 2026 YTD | $305.1 | $244.7 | -20% |
IBM has finished higher in five of the last six years. It's down 20% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over IBM on returns for 2026, with the stronger performance.